Higher Death Rate Forces Bayer to Stop Xofigo/Zytiga Combo Late-Stage Study Early

An IDMC told Bayer that it should unblind its Phase III clinical trial in prostate cancer in order to further analyze an increased number of fractures and deaths.
Source: BioSpace